EMpagliflozin and daPAgliflozin in patients hospiTalized for acute decompensated Heart failure (EMPATHY trial)
Acronym
EMPATHY
Project Title
EMpagliflozin and daPAgliflozin in patients hospiTalized for acute decompensated Heart failure (EMPATHY trial)
![](/sites/pnitt.wum.edu.pl/files/styles/medium/public/Logo%20ABM04_1.jpg?itok=ceXG1oxX)
Financing Institution
Medical Research Agency
Medical Research Agency
Lead
Prof. dr hab. Marek Postuła Prof. dr hab. Jolanta Siller-Matula
Subject
EMpagliflozin and daPAgliflozin in patients hospiTalized for acute decompensated Heart failure (EMPATHY trial)
Project Objective
The aim of the project is the assessment of:
1) influence of SGLT-2 inhibitors (Empagliflozin and Dapagliflozin) on primary and secondary clinical end-points in patients with acute/unstable heart failure (AHF);
2) influence of SGLT-2 inhibitors on heart rate;
3) influence of SGLT-2 inhibitors on biomarkers and circulating micro RNA (miRNA) and microbiome metabolites
4) proposing a risk prognosis scale in order to closely monitor the course of AHF and its treatment with SGLT-2 inhibitors based on selected miRNA and biomarkers related to molecular trails related to the course of the disease